Alexander Frank, MD
Family Medicine · Oklahoma City, OKNPI 1164450573
Payments from drug & device makers
What this record shows
This record is dominated by other: $3,082,225 of the $3,090,489 with a category attached, or 99.7%. Skye Orthobiologics LLC accounts for 99.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $3,082,225 and has fallen 100.0% since, to $234 in 2025. Among family medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $14,242 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Skye Orthobiologics LLC$3.1M
- Johnson & Johnson$4K
- Acadia Pharmaceuticals Inc$1K
- Avanir Pharmaceuticals, Inc.$684
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$552
- Novartis$258
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$3,5600%
- Travel & lodging$6840%
- Food & beverage$4,0200%
- Other$3,082,225100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Skye Orthobiologics LLC | 1 | $3,082,225 |
| Johnson & Johnson | 15 | $4,469 |
| Acadia Pharmaceuticals Inc | 24 | $1,157 |
| Avanir Pharmaceuticals, Inc. | 83 | $684 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $552 |
| Novartis | 15 | $258 |
| Corium, LLC | 5 | $187 |
| Gilead | 7 | $164 |
| Neurocrine Biosciences, Inc. | 1 | $136 |
| Sun Pharmaceutical Industries Inc. | 2 | $129 |
| Teva Pharmaceuticals USA, Inc. | 6 | $92 |
| Sunovion Pharmaceuticals Inc. | 4 | $77 |
| UCB, Inc. | 3 | $62 |
| Smith+Nephew | 3 | $52 |
| GSK | 2 | $36 |
| Indivior Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $32 |
| Sumitomo Pharma America, Inc. | 3 | $27 |
| Urovant Sciences Inc | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$4,244
- NUPLAZID$574
- INGREZZA$136
- ENTRESTO$125
- DRIZALMA SPRINKLE$110
- EZALLOR SPRINKLE$110
- KAPSPARGO$110
- CAPLYTA$108
How this compares
$3,090,489 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,067 | $374,463 |
| Invega SustennaPaliperidone Palmitate | 87 | $264,237 |
| VraylarCariprazine Hcl | 264 | $263,372 |
| AristadaAripiprazole Lauroxil | 57 | $180,362 |
| TrulicityDulaglutide | 125 | $115,200 |
| NuedextaDextromethorphan Hbr/Quinidine | 119 | $92,781 |
| Abilify MaintenaAripiprazole | 30 | $90,611 |
| RexultiBrexpiprazole | 61 | $76,098 |
| CibinqoAbrocitinib | 12 | $68,168 |
| JanuviaSitagliptin Phosphate | 206 | $66,401 |
| XareltoRivaroxaban | 201 | $66,005 |
| JardianceEmpagliflozin | 146 | $56,605 |
| TrintellixVortioxetine Hydrobromide | 169 | $56,217 |
| FarxigaDapagliflozin Propanediol | 169 | $53,682 |
| Riluzole | 303 | $51,546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Xarelto | $4,469 | $330,243288 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $15 | $166,70991 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $32 | $139,590985 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $684 | $92,781119 claims |
| NovartisEntresto | $258 | $50,895122 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta | $36 | $42,26393 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $27 | $14,51941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
- Jonathon KnoxOklahoma City$20K
- Steven SacketOklahoma City$17K
- Stanley CorleyOklahoma City$16K
- Teddy WebbOklahoma City$15K
- Judy MagnussonOklahoma City$14K
- Ryan GotcherOklahoma City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.